Literature DB >> 26134438

Assessment of Treatment Response With Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI in Patients With Early-Stage Breast Cancer Treated With Single-Dose Preoperative Radiotherapy: Initial Results.

Chunhao Wang1, Janet K Horton1, Fang-Fang Yin1, Zheng Chang2.   

Abstract

Single-dose preoperative stereotactic body radiotherapy is a novel radiotherapy technique for the early-stage breast cancer, and the treatment response pattern of this technique needs to be investigated on a quantitative basis. In this work, dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging were used to study the treatment response pattern in a unique cohort of patients with early-stage breast cancer treated with preoperative radiation. Fifteen female qualified patients received single-dose preoperative radiotherapy with 1 of the 3 prescription doses: 15 Gy, 18 Gy, and 21 Gy. Magnetic resonance imaging scans including both diffusion-weighted magnetic resonance imaging and dynamic contrast-enhanced magnetic resonance imaging were acquired before radiotherapy for planning and after radiotherapy but before surgical resection. In diffusion-weighted magnetic resonance imaging, the regional averaged apparent diffusion coefficient was calculated. In dynamic contrast-enhanced magnetic resonance imaging, quantitative parameters K (trans) and v e were evaluated using the standard Tofts model based on the average contrast agent concentration within the region of interest, and the semiquantitative initial area under the concentration curve (iAUC6min) was also recorded. These parameters' relative changes after radiotherapy were calculated for gross tumor volume, clinical target volume, and planning target volume. The initial results showed that after radiotherapy, initial area under the concentration curve significantly increased in planning target volume (P < .006) and clinical target volume (P < .006), and v e significantly increased in planning target volume (P < .05) and clinical target volume (P < .05). Statistical studies suggested that linear correlations between treatment dose and the observed parameter changes exist in most examined tests, and among these tests, the change in gross tumor volume regional averaged apparent diffusion coefficient (P < .012) and between treatment dose and planning target volume K (trans) (P < .029) were found to be statistically significant. Although it is still preliminary, this pilot study may be useful to provide insights for future works.
© The Author(s) 2015.

Entities:  

Keywords:  breast cancer; breast single-dose preoperative radiotherapy; diffusion-weighted MRI; dynamic contrast-enhanced MRI; treatment assessment

Mesh:

Year:  2015        PMID: 26134438      PMCID: PMC4914478          DOI: 10.1177/1533034615593191

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  45 in total

1.  Rigid point feature registration using mutual information.

Authors:  A Rangarajan; H Chui; J S Duncan
Journal:  Med Image Anal       Date:  1999-12       Impact factor: 8.545

2.  Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Kenya Murase
Journal:  Magn Reson Med       Date:  2004-04       Impact factor: 4.668

Review 3.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.

Authors:  James P B O'Connor; Alan Jackson; Geoff J M Parker; Caleb Roberts; Gordon C Jayson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-14       Impact factor: 66.675

4.  Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI.

Authors:  Piet Dirix; Vincent Vandecaveye; Frederik De Keyzer; Sigrid Stroobants; Robert Hermans; Sandra Nuyts
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

Review 5.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

Review 6.  Review of treatment assessment using DCE-MRI in breast cancer radiation therapy.

Authors:  Chun-Hao Wang; Fang-Fang Yin; Janet Horton; Zheng Chang
Journal:  World J Methodol       Date:  2014-06-26

Review 7.  Brachytherapy for partial breast irradiation: the European experience.

Authors:  Csaba Polgár; Vratislav Strnad; Tibor Major
Journal:  Semin Radiat Oncol       Date:  2005-04       Impact factor: 5.934

8.  Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis.

Authors:  Silvia C Formenti; Minh Tam Truong; Judith D Goldberg; Vandana Mukhi; Barry Rosenstein; Daniel Roses; Richard Shapiro; Amber Guth; J Keith Dewyngaert
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-10-01       Impact factor: 7.038

Review 9.  Tumor microenvironmental physiology and its implications for radiation oncology.

Authors:  Peter Vaupel
Journal:  Semin Radiat Oncol       Date:  2004-07       Impact factor: 5.934

10.  Water diffusion in the different microenvironments of breast cancer.

Authors:  Yael Paran; Peter Bendel; Raanan Margalit; Hadassa Degani
Journal:  NMR Biomed       Date:  2004-06       Impact factor: 4.044

View more
  7 in total

1.  Evaluation of the effect of transcytolemmal water exchange analysis for therapeutic response assessment using DCE-MRI: a comparison study.

Authors:  Chunhao Wang; Ergys Subashi; Xiao Liang; Fang-Fang Yin; Zheng Chang
Journal:  Phys Med Biol       Date:  2016-06-08       Impact factor: 3.609

2.  Accelerated Brain DCE-MRI Using Iterative Reconstruction With Total Generalized Variation Penalty for Quantitative Pharmacokinetic Analysis: A Feasibility Study.

Authors:  Chunhao Wang; Fang-Fang Yin; John P Kirkpatrick; Zheng Chang
Journal:  Technol Cancer Res Treat       Date:  2016-05-23

3.  Early response assessment after CyberKnife stereotactic radiosurgery for symptomatic vertebral hemangioma by quantitative parameters from dynamic contrast-enhanced MRI.

Authors:  Hongqing Zhuang; Ning Lang; Yongye Chen; Enlong Zhang; Qizheng Wang; Huishu Yuan
Journal:  Eur Spine J       Date:  2021-03-01       Impact factor: 3.134

4.  Assessment of concurrent stereotactic radiosurgery and bevacizumab treatment of recurrent malignant gliomas using multi-modality MRI imaging and radiomics analysis.

Authors:  Chunhao Wang; Wenzheng Sun; John Kirkpatrick; Zheng Chang; Fang-Fang Yin
Journal:  J Radiosurg SBRT       Date:  2018

5.  Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol.

Authors:  R K Charaghvandi; B van Asselen; M E P Philippens; H M Verkooijen; C H van Gils; P J van Diest; R M Pijnappel; M G G Hobbelink; A J Witkamp; T van Dalen; E van der Wall; T C van Heijst; R Koelemij; M van Vulpen; H J G D van den Bongard
Journal:  BMC Cancer       Date:  2017-03-09       Impact factor: 4.430

6.  DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR.

Authors:  Matthew Mouawad; Heather Biernaski; Muriel Brackstone; Michael Lock; Brian Yaremko; Olga Shmuilovich; Anat Kornecki; Ilanit Ben Nachum; Giulio Muscedere; Kalan Lynn; Frank S Prato; R Terry Thompson; Stewart Gaede; Neil Gelman
Journal:  Clin Transl Radiat Oncol       Date:  2019-12-25

7.  Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation.

Authors:  Jeanine E Vasmel; Maureen L Groot Koerkamp; Stefano Mandija; Wouter B Veldhuis; Maaike R Moman; Martijn Froeling; Bas H M van der Velden; Ramona K Charaghvandi; Celien P H Vreuls; Paul J van Diest; A M Gijs van Leeuwen; Joost van Gorp; Marielle E P Philippens; Bram van Asselen; Jan J W Lagendijk; Helena M Verkooijen; H J G Desirée van den Bongard; Antonetta C Houweling
Journal:  Adv Radiat Oncol       Date:  2021-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.